Drug Research
Drug Delivery

Drug Delivery News

View news from other Pharmaceutical sectors:
61-75 of 2325 results
TetraLogic sells SMAC Mimetic and HDAC Inhibitor assets to Medivir
TetraLogic Pharmaceuticals has completed the sale of its SMAC Mimetic and HDAC Inhibitor assets to Medivir.
Drug Research > Drug Delivery > News
Clinigen to distribute BioQ Pharma’s pain relief drug in Europe
Clinigen Group’s Idis Global Access (GA) division has signed a supply and distribution agreement with ready-to-use infusible products developer BioQ Pharma.
Drug Research > Drug Delivery > News
Baxter to acquire Claris Injectables for $625m
By PBR Staff Writer
US drug maker Baxter International has agreed to acquire Claris Lifesciences' injectables business for about $625m.
Drug Research > Drug Delivery > News
Proton Partners to build new cancer center in Reading, UK
Proton Partners International has secured formal planning permission to establish a new cancer treatment center in Reading, Berkshire, UK.
Drug Research > Drug Delivery > News
Cardiome Pharma launches Xydalba (dalbavancin) in UK
Cardiome Pharma has launched XYDALBA for injection, a second-generation, semi-synthetic lipoglycopeptide, in the UK earlier than expected.
Drug Research > Drug Delivery > News
Endo returns rights for BELBUCA to BioDelivery Sciences International
Endo International has entered into an agreement with its partner, BioDelivery Sciences International (BDSI), to return the BELBUCA (buprenorphine) buccal film product to BDSI.
Drug Research > Drug Delivery > News
GlobalData says NSCLC market will increase to $26.71bn by 2025
Research and consulting firm GlobalData said the non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to increase to $26.71bn by 2025 from $6.21bn in 2015, representing a very strong compound annual growth rate of 15.7%.
Drug Research > Drug Delivery > News
FDA approves DARZALEX for relapsed multiple myeloma
Genmab has secured approval from the US Food and Drug Administration (FDA) to use DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug Research > Drug Delivery > News
Immune Pharmaceuticals secures up to $11m in new financing
Immune Pharmaceuticals has secured up to $11m in new financing, which will be deployed with a focus on bertilimumab clinical development.
Drug Research > Drug Delivery > News
Albireo’s lead product candidate for PFIC accepted into EMA's PRIME Program
Albireo Pharma's lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) to treat progressive familial intrahepatic cholestasis (PFIC).
Drug Research > Drug Delivery > News
Midatech Pharma selects MTR104 candidate for liver cancer treatment
Midatech Pharma has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018.
Drug Research > Drug Delivery > News
Pfizer’s Celebrex found to be no riskier for hearts than other rival pain drugs
By PBR Staff Writer
A new study has found that Pfizer’s arthritis drug Celebrex (celecoxib) posed no higher risk to a patient’s heart when compared to its rivals, Ibuprofen and Naproxen.
Drug Research > Drug Delivery > News
Amgen partners with Janssen to co-fund studies with KYPROLIS and DARZALEX in multiple myeloma
Amgen and Janssen Pharmaceuticals are collaborating in multiple clinical trials assessing the combination of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in patients with multiple myeloma (MM).
Drug Research > Drug Delivery > News
Therapix completes formulation development for tablet for sublingual administration of pharmaceutical use
Therapix Biosciences has completed the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use.
Drug Research > Drug Delivery > News
EC grants orphan drug designation to Philogen's soft tissue sarcoma treatment
Philogen has secured Orphan Drug Designation from the European Commission (EC) to L19TNF - a non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format - for the treatment of soft-tissue sarcoma.
Drug Research > Drug Delivery > News
61-75 of 2325 results